Should angiotensin II receptor blockers and statins be combined?
Nickenig
Georg
G
Department of Internal Medicine III, University Hospital of the Saarland, Homburg/Saar, Germany. nickenig@med-in.uni-saarland.de
D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage* / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000209:etiology / Q000517:prevention & control*; D048909:Diabetes Complications / Q000188:drug therapy / Q000503:physiopathology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000503:physiopathology; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy; D018384:Oxidative Stress; D011817:Rabbits; D044140:Receptor, Angiotensin, Type 1 / Q000502:physiology; D044139:Receptor, Angiotensin, Type 2 / Q000502:physiology; D012084:Renin-Angiotensin System / Q000502:physiology; D020521:Stroke / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D014661:Vasoconstriction
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2